Long acting injectable formulation comprising risperidone and biodegradable polymers
US12329851B2 · kind B2 · utility
0Cited by
1References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 23, 2024 |
| Grant date | Jun 17, 2025 |
| Priority date | — |
| Expiry date | Feb 23, 2044 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to methods of treating psychiatric diseases and disorders comprising administering to a subject in need thereof at a frequency of no more than once every 28 days an injectable formulation comprising risperidone, triblock and diblock copolymers wherein the concentration of the risperidone is 250-400 mg/mL and injection volume is 1 mL or less.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.